Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
Authors
Keywords
-
Journal
Nature Communications
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-11-20
DOI
10.1038/ncomms3773
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
- (2013) J. I. Siner et al. BLOOD
- Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
- (2013) J. McIntosh et al. BLOOD
- Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A
- (2012) J M Johnston et al. GENE THERAPY
- Recent Progress in Gene Therapy for Hemophilia
- (2012) Marinee K. Chuah et al. HUMAN GENE THERAPY
- Modern haemophilia care
- (2012) Erik Berntorp et al. LANCET
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection
- (2011) A. Biffi et al. BLOOD
- Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
- (2011) C. R. M. Hay et al. BLOOD
- Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk
- (2011) Janka Mátrai et al. HEPATOLOGY
- Successful Pregnancy After Busulfan/Cytoxan Conditioning Regimen for AML
- (2011) Ami J. Shah JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs
- (2011) T. C. NICHOLS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
- (2011) Amit C. Nathwani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet gene therapy improves hemostatic function for integrin IIb 3-deficient dogs
- (2011) J. Fang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors
- (2010) Denise E Sabatino et al. MOLECULAR THERAPY
- Beyond Clotting: The Powers of Platelets
- (2010) M. Leslie SCIENCE
- Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
- (2009) D. E. Sabatino et al. BLOOD
- A study of variations in the reported haemophilia A prevalence around the world
- (2009) J. S. STONEBRAKER et al. HAEMOPHILIA
- Stable Marking and Transgene Expression Without Progression to Monoclonality in Canine Long-Term Hematopoietic Repopulating Cells Transduced with Lentiviral Vectors
- (2009) Joerg Enssle et al. HUMAN GENE THERAPY
- Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A
- (2009) Christopher B Doering et al. MOLECULAR THERAPY
- Inhibitors of Factor VIII in Black Patients with Hemophilia
- (2009) Kevin R. Viel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji
- (2008) Jin Huk Choi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started